Evidence map›Paper›PMID 42239520›Full record

ReviewFrontiers in pharmacology2026

Pharmacogenomics of treatment toxicities in pediatric B-Cell ALL: toward safer precision therapy.

Meriem Lameri, Tarek Kamergi, Ameni Brahim, Imen Abdallah, Nessrine Mezzi, Sarah Zerei, Alia Benkahla, Manel Chaabane, Chema Drira, Hajer Felfel and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Meriem LameriCentre National de Transfusion Sanguine, Tunis, Tunisia.
Tarek KamergiCentre National de Greffe de la Moelle Osseuse, Tunis, Tunisia.
Ameni BrahimDepartment of Biochemistry, LR12SP11, Hopital Sahloul, Sousse, Tunisia.
Imen AbdallahLaboratory of Biomedical Genomics and Oncogenetics, LR 16 IPT 05, Institut Pasteur de Tunis, Tunis, Tunisia.
Nessrine MezziLaboratory of Biomedical Genomics and Oncogenetics, LR 16 IPT 05, Institut Pasteur de Tunis, Tunis, Tunisia.
Sarah ZereiPharmaceutical Sciences A Department, Clinical Biology A Department, Universite de Monastir, Faculte de Pharmacie de Monastir, Monastir, Tunisia.
Alia BenkahlaBioinformatics Laboratory, Biomathematics, and Biostatistics (LR16IPT09), Institut Pasteur de Tunis, Tunis, Tunisia.
Manel ChaabaneCentre National de Transfusion Sanguine, Tunis, Tunisia.
Chema DriraCentre National de Greffe de la Moelle Osseuse, Tunis, Tunisia.
Hajer FelfelPharmaceutical Sciences B Department, Universite de Monastir, Faculte de Pharmacie de Monastir, Monastir, Tunisia.
Yosr Ben AbdennebiPediatric Clinical Hematology, Hopital Aziza Othmana, Tunis, Tunisia.
Miriam Razgallah KhroufPharmaceutical Sciences A Department, Clinical Biology A Department, Universite de Monastir, Faculte de Pharmacie de Monastir, Monastir, Tunisia.
Dorra AmorPharmaceutical Sciences A Department, Clinical Biology A Department, Universite de Monastir, Faculte de Pharmacie de Monastir, Monastir, Tunisia.
Lilia RomdhaneLaboratory of Biomedical Genomics and Oncogenetics, LR 16 IPT 05, Institut Pasteur de Tunis, Tunis, Tunisia.
Hend ChakerLaboratory of Biomedical Genomics and Oncogenetics, LR 16 IPT 05, Institut Pasteur de Tunis, Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacogenomics (PGx) has emerged as a key strategy to predict and prevent drug hypersensitivity reactions and treatment-related toxicities, thereby improving therapeutic adherence and survival in cancer care. Despite major advances in survival outcomes for pediatric B-Acute Lymphoblastic Leukemia (B-ALL), treatment-related toxicities remain a significant clinical challenge. Notably, treatment de-escalation strategies for low-risk leukemia are currently being explored in several clinical trials to reduce therapy-related toxicities. This review focuses on the mechanisms of drug-induced toxicity and their association with pharmacogenetic determinants in B-ALL therapy. Among the pharmacogenetic factors influencing toxicity of commonly used B-ALL treatments, variants in the

Indexed as

acute lymphoblastic leukemiadrug toxicitygenotype-guided therapyNUDT15pharmacogenomicsprecision medicineTPMT

Identifiers

PMID42239520
PMCPMC13226516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.